SPX3,998.84-72.86 -1.79%
DIA340.03-4.71 -1.37%
IXIC11,239.94-221.56 -1.93%

--JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $81, Maintains Overweight Rating

--JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $81, Maintains Overweight Rating

MT Newswires · 11/16/2022 04:03

Please log in to view news